New pill trial targets rare, returning blood cancer
NCT ID NCT07387471
Summary
This study is testing whether a pill called venetoclax can help control a rare type of blood cancer called Waldenström macroglobulinemia in Japanese adults whose cancer has come back or stopped responding to prior treatments. About 14 participants will take the pill daily, with doses increasing to a target level over time. Doctors will monitor how the cancer responds and check for side effects over approximately 28 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NHO Mito Medical Center /ID# 279175
RECRUITINGHigashiibaraki-gun, Ibaraki, 311-3193, Japan
-
National Cancer Center Hospital /ID# 279076
RECRUITINGChuo-Ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Disaster Medical Center /ID# 277741
RECRUITINGTachikawa, Tokyo, 190-0014, Japan
Conditions
Explore the condition pages connected to this study.